Stage IIIC Cutaneous Melanoma AJCC v7 Completed Phase 2 Trials for Aldesleukin (DB00041)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01258855Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment